Driving Lifecycle Management Excellence Across the Full Product Lifecycle

Driving Lifecycle
With customers accelerating their move towards digital (triggered by Covid-19), omnichannel thinking should be a key dimension of your 2023 business planning.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Membrane-Based Water for Injection

ON24

Historically, distillation has been the most common technology used to produce Water for Injection (WFI), due to prior process advantages and historical regulatory requirements. Changes in the European Pharmacopeiano longer require the use of distillation systems to produce WFI. In this webcast, learn about the impact of this regulatory change on water system design and how reverse osmosis and ultrafiltration can be used to produce WFI with significant lifecycle cost advantages.
Watch Now

The top 5 cybersecurity threats to pharma for 2022

It's no secret that pharma companies are struggling to protect themselves from cyberattacks amid the pandemic. Data breaches are costing the sector around US$5m a year, while one in 10 pharma companies are at risk of a ransomware attack, exacerbated by a perfect storm of shifting to remote working, increased growth, antiquated OT systems and a lack of cybersecurity skills.
Watch Now

Improving Sterilising Filtration in the Biopharmaceutical Industry

business-review-webinars

Sterile filtration has been a cornerstone of bioprocessing for over 60 years and as the industry continues its change from stainless steel to single-use, filtration has also evolved, moving from cartridge to capsule format with several membrane types to choose from. This webinar aims to provide an overview of filtration in bioprocessing addressing key considerations when developing a biopharmaceutical manufacturing process.
Watch Now

Using Real World Evidence to Build Dynamic Cohorts in Real-Time

Marklogic

After the US Food and Drug Administration (FDA)’s stated that “the clinical trial system is broken,” regulatory agencies began working to formally figure out how real-world evidence will be used in new drug submissions and for new uses of existing drugs. The business potential is huge: organizations can reduce the time and cost of bringing new drugs to market by relying on existing real-world data and new sources of unstructured data, e.g., EHRs and social media. Most importantly, this real-world data can get patient-saving drugs to market more quickly with fewer post-release adverse events.
Watch Now

Spotlight

resources